STRUCTURAL ANALYSIS OF ENZYMES FOR ARCHIDONATE CASCADE FOR DEVELOPING NOVEL DRUGS

用于开发新药的阿基多酸级联酶的结构分析

基本信息

批准号：
15310158
负责人：
INOUE Hiroyasu
金额：
$ 8.7万
依托单位：
Nara Women's University (2004-2005)National Cardiovascular Center Research Institute (2003)
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2003
资助国家：
日本
起止时间：
2003 至 2005
项目状态：
已结题

项目摘要

It is widely accepted that effects of nonsteroidal anti-inflammatory drugs (NSAIDs) result from inhibition of cyclooxygenase (COX) activities. COX has two isoforms, constitutive enzyme COX-1 and inducible enzyme COX-2. COX-2 selective inhibitors are considered as promised NSAIDs with low side effects derived from inhibition of COX-1 activity. However, recent reports show COX-2 selective inhibitors have also side effects such as increase risk of serious coronary heart disease, indicating a growing need for searching other drug targets. As one of the novel targets, microsomal prostaglandin E synthase (mPGES) is noteworthy because it is more selectively induced than COX-2 in inflammatory sites. On the other hand, 5-lipoxygenase activating protein (FRAP), a member of the same family of mPGES, and peroxisome proliferator-activated receptor (PPAR), a member of nuclear receptor superfamily, are recognized as drug targets against lifestyle-related diseases. We found that resveratrol, a polyphenol contained in red wines, is a dual agonist for PPARα and γ, and that resveratrol protects the brain against ischemia by activation of PPARα. Remarkably, MK-886, a dual inhibitor for mPGES and FLAP is reported to be a PPARα antagonist, indicating the possibility of the side effect of mPGES inhibitor by its antagonistic activity for PPAR. The aim of this study is to determine the three-dimensional structures of mPGES, FLAP and PPARα for development of novel drugs based on their structures. We successfully expressed and purified these recombinant proteins, and are still investigating the conditions for their good crystallization. We obtained a protein crystal for FLAP by the lipidic cubic phase method, which is a newly developed.

人们普遍认为，非甾体类抗炎药（NSAID）的作用是抑制环氧酶（COX）活性引起的。 Cox具有两个同工型，组成酶COX-1和诱导酶COX-2。 COX-2选择性抑制剂被视为承诺的NSAID，具有抑制COX-1活性的低副作用。但是，最近的报告显示，COX-2选择性抑制剂还具有副作用，例如增加严重冠心病的风险，表明对其他药物靶标的需求日益增加。作为新的靶标，微粒体前列腺素E合酶（MPGE）值得注意，因为它比炎症部位中的COX-2更有选择性。另一方面，同一MPGE家族的成员和核受体超家族成员的5-脂氧合酶激活蛋白（FRAP）和过氧化物组增殖物激活受体（PPAR）被公认为是针对生活方式相关疾病的药物靶标。我们发现白藜芦醇是红葡萄酒中包含的多酚，是PPARα和γ的双重激动剂，并且白藜芦醇通过激活PPARα保护大脑免受缺血保护。值得注意的是，据报道，MK-886是MPGES和皮瓣的双重抑制剂是PPARα拮抗剂，表明MPGES抑制剂的副作用是通过其对PPAR的拮抗活性而产生的。这项研究的目的是根据其结构确定MPGE，皮瓣和PPARα的三维结构，以开发新的药物。我们成功表达并纯化了这些重组蛋白，并且仍在研究其良好结晶的条件。我们通过脂质立方相法获得了蛋白质晶体，这是新开发的。

项目成果

期刊论文数量（80）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor α in mice

DOI：
10.1016/j.neulet.2003.09.001
发表时间：
2003-12-11
期刊：
NEUROSCIENCE LETTERS
影响因子：
2.5
作者：
Inoue, H;Jiang, XF;Namura, S
通讯作者：
Namura, S

Temporal and topographic profiles of cyclooxygenase-2 expression during 24 h of focal brain ishemia in rats.

大鼠局灶性脑缺血 24 小时期间环氧合酶 2 表达的时间和地形特征。

DOI：
发表时间：
2004
期刊：
Neurosci Lett. 357
影响因子：
0
作者：
C.Yokota;T.Kaji;Y.Kuge;H.Inoue;N.Tamaki;K.Minematsu
通讯作者：
K.Minematsu

Helicobacter pylori promote gastric cancer cells invasion through a NF-κB and COX-2-mediated pathway

DOI：
10.3748/wjg.v11.i21.3197
发表时间：
2005-06-07
期刊：
WORLD JOURNAL OF GASTROENTEROLOGY
影响因子：
4.3
作者：
Wu, Chun-Ying;Wang, Chau-Jong;Chen, Gran-Hum
通讯作者：
Chen, Gran-Hum

Cyclooxygenase-2 expression associated with spreading depression in a primate model.

环加氧酶 2 的表达与灵长类动物模型中抑郁症的扩散相关。

DOI：
发表时间：
2003
期刊：
Journal of Cerebral Blood Flow & Metabolism 23
影响因子：
0
作者：
Yokota C;Inoue H;Kuge Y;Abumiya T;Tagaya M;Hasegawa Y;Ejima N;Tamaki N;Minematsu K
通讯作者：
Minematsu K

Hypertonic sodium chloride induction of cyclooxygenase-2 occurs independently of NF-kappaB and is inhibited by the glucocorticoid receptor in A549 cells.

高渗氯化钠诱导环加氧酶-2 的发生独立于 NF-κB，并受 A549 细胞中糖皮质激素受体的抑制。